The goal of this clinical research study is to add the anti-diabetic
drug metformin to standard treatment for lung cancer (radiation therapy
and chemotherapy) is more effective than standard treatment alone. The
addition of metformin to the usual radiation and chemotherapy could
shrink your cancer more than the usual radiation and chemotherapy alone
and help prevent it from returning, but it could also cause side
effects. This study will allow the researchers to know whether adding
metformin to radiation and chemotherapy is better, the same, or worse
than radiation and chemotherapy alone. Metformin is already
FDA-approved for use in diabetes, and studies have shown that it is
safe for use in non-diabetic patients. There will be about 168 people
taking part in this study.